

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

HOLOGIC, INC.,  
Petitioner

v.

ENZO LIFE SCIENCES, INC.  
Patent Owner

---

U.S. Patent No. 7,064,197

**SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT  
COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS**

---

**DECLARATION OF DR. NORMAN NELSON**

**Table of Contents**

I. QUALIFICATION AND EXPERIENCE.....1

II. RELEVANT LEGAL STANDARDS .....3

III. LEVEL OF ORDINARY SKILL IN THE ART .....6

IV. SUMMARY OF MY OPINIONS .....7

V. THE '197 PATENT.....9

VI. CLAIMS 1, 6, 8, 9, 12, 13, 14, 15, 16, 27, 31, 32, 33, 34, 41, 61, 62, 63, 68, 69, 70, 72, 73, 74, 79, 100, 191, 192, 193, 194, 212, 213, 219, 222, 225, 226, 227, 230, 233, AND 236 ARE ANTICIPATED BY FISH.....11

    A. Fish (Ex. 1008).....11

    B. Fish discloses surface treatment of plastic microtitration trays with poly-L-lysine to bind nucleic acids in hybridizable form to the surface of the microtitration wells.....12

VII. CLAIMS 31, 64, 68, 101, 192, AND 195 WOULD HAVE BEEN OBVIOUS IN VIEW OF FISH.....27

VIII. CLAIMS 38, 78, AND 218 WOULD HAVE BEEN OBVIOUS BASED ON FISH IN VIEW OF GILHAM.....29

IX. CLAIMS 1, 6, 8, 9, 12, 13, 14, 15, 27, 31, 32, 34, 61, 62, 63, 68, 69, 70, 72, 74, 79, 100, 191, 192, 193, 194, 213, 219, 226, 227, AND 236 ARE ANTICIPATED BY VPK. ....31

    A. Van Prooijen-Knegt (Ex. 1008, "VPK").....31

    B. VPK discloses surface treatment of glass slides with alkylaminosilane to bind nucleic acids in hybridizable form to the surface of the glass slides .....32

X. CLAIMS 16, 38, 64, 78, 101, 195, 218, 222, AND 230 WOULD HAVE BEEN OBVIOUS BASED ON NOYES IN VIEW OF VPK AND FURTHER IN VIEW OF RAMACHANDRAN.....36

XI. CLAIMS 33, 41, 73, 212, 225, AND 233 WOULD HAVE BEEN  
OBVIOUS BASED ON VPK IN VIEW OF METZGAR .....41

XII. CONCLUSION.....42

LIST OF MATERIALS CONSIDERED..... i

I, Norman Nelson, do hereby declare:

1. I am making this declaration at the request of Hologic, Inc. (“Hologic”) in the matter of the *Inter Partes* Review of U.S. Patent No. 7,064,197 to Rabbani et al. (“the ’197 patent”).
2. My qualifications are established by my resume, which I understand is provided as Exhibit A to this Declaration.
3. I am being compensated for my work on this matter, but my opinions are based on my own views of the patented technology and the prior art. My compensation in no way depends on the outcome of this proceeding or the content of my testimony.
4. In preparing this Declaration, I reviewed and considered the ’197 patent, the prosecution history of the ’197 patent, and the documents listed at the end of this declaration. Importantly, I have reviewed the related Petition, which I understand Hologic will file at the United States Patent and Trademark Office (USPTO) at the same time as this Declaration is filed at the USPTO.

#### **I. QUALIFICATION AND EXPERIENCE**

5. I obtained a Ph.D. in Chemistry, with a focus in Biochemistry, in 1982 from University of California, San Diego. I also received a Bachelor of Science in Chemistry from California Institute of Technology in 1976.

6. I have nearly 31 years of experience in molecular diagnostics and nucleic acid chemistry, particularly nucleic acids analysis. I am and was very knowledgeable about conventional techniques for attaching nucleic acids to other moieties like solid supports or labels. I worked for Gen-Probe Incorporated (now acquired by Hologic, Inc.)—a pioneer and leader in molecular diagnostics—for 27 years (June 1985-August 2012). While at Gen-Probe, I co-invented, reduced to practice, and played a key role in commercialization of multiple core technologies involving nucleic acids analysis, which are currently in FDA-approved products.
7. I started my career at Gen-Probe as a scientist (1985-2005), where I developed and implemented key nucleic acids-based technologies and assays, including nucleic acids capture/immobilization and labeling techniques, hybridization, amplification and detection of nucleic acids. As the Director of Biochemistry at Gen-Probe (2005-2009), I led a multidisciplinary team in the development of multiplexed nucleic acids-based assays. And as the Senior Director of Discovery Research at Gen-Probe (2009-2012), I focused on the development and commercialization of various nucleic acids-based diagnostic products.
8. I have been working as a consultant in the field of nucleic acids-based diagnostics, DNA sequencing and Genomics since 2012.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.